Skip to main content
IBRX logo

ImmunityBio, Inc. (IBRX) Stock: Price, Forecast & Analyst Target

ImmunityBio, Inc. (IBRX) — MoonshotScore 12/100 (Weak band), calculated Nov 18, 2026. Price $6.57 (-1.94%), as of the Nov 19, 2026 trading session; market cap $6.99B.

Educational signal · not a buy or sell recommendation · How to read this

$6.57 −$0.13 (-1.94%) Market Cap $6.99B

ImmunityBio, Inc. · IBRX · NASDAQ · Healthcare · Biotechnology

Research dated 2026-09-13 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered): Nasdaq-listed ImmunityBio develops immunotherapies and cell therapies for cancers and infectious diseases, while reported revenue now comes overwhelmingly from product sales. That makes it more than a pipeline biotechnology story, but not yet a self-funding commercial company. The case depends on whether rising product revenue can overtake research, selling, and financing demands before cash consumption forces further balance-sheet action.

Price as of Nov 19, 2026

Key Statistics

12 of 100

MoonshotScore v2 · ImmunityBio (IBRX)

Weak
Business Quality Thin (23)
Financial Safety Strained (37)
Valuation Full (44)
Growth Durability Growing (64)
Momentum Surging (82)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Only growth holds up — quality and the balance sheet are near the sector floor; far more to fix here than to build on, and it’s expensive on top. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Thin; Financial Safety: Strained; Valuation: Full; Growth Durability: Growing; Momentum: Surging.

  • EPS beat 3 of the last 8 reports
  • Altman Z -13.30 · Piotroski F 3
  • ROE 124.6% · current ratio 4.27 · earnings yield -17.5% · free-cash-flow yield -4.7%

Holding back: weak fundamentals

Helping: positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for IBRX (57 recorded, newest six shown)
RecordedScoreBand
13Weak
13Weak
13Weak
13Weak
12Weak
12Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$6.57
Change on the day-1.94%
52-week range$1.95–$12.43
Market capitalisation$6.99B—
Shares traded on the day10.88M
Beta (volatility vs the S&P 500)0.13

Why ImmunityBio scores 12

Dr. Mira Sol, the Stock Expert AI TV data character
Momentum carries the score; Business Quality is what holds it back.
Dr. Mira Sol · Data scientist, Stock Expert AI TV (fictional AI character)
12Weak
  • Business Quality23
  • Financial Safety37
  • Valuation44
  • Growth Durability64
  • Momentum82

Share price, last 12 months +211.7%

$2.14 $6.67

How the stock reacts to earnings

EPS beat in 4 of the last 12 reports (2024–2026); the stock still fell the next session after 3 of those beats. Average first-session move: 11.6% either way.

  1. +14.5%Mar ’24
  2. +2.5%May ’24
  3. -17.2%Aug ’24
  4. -11.4%Nov ’24
  5. -8.2%Mar ’25
  6. +21.3%May ’25
  7. -1.2%Aug ’25
  8. -4.9%Nov ’25
  9. +32.8%Feb ’26
  10. +1.6%May ’26
  11. +1.4%Aug ’26
  12. -21.9%Nov ’26
Next-session move EPS beat (4) EPS in line (1) EPS miss (7)
Every report, with revenue and five-session moves
Moves run from the close before the report to the first and fifth closes after it.
ReportEPSRevenueNext session5 sessions
MissMiss-21.9%—
MissBeat+1.4%+6.3%
MissBeat+1.6%-2.7%
BeatIn line+32.8%+20.0%
BeatMiss-4.9%-5.3%
In lineMiss-1.2%+2.5%
MissIn line+21.3%+35.3%
BeatMiss-8.2%-11.6%
BeatMiss-11.4%-1.8%
MissMiss-17.2%-11.9%
MissBeat+2.5%-2.1%
MissBeat+14.5%-2.1%

The market has been forgiving after misses, which says investors are looking past the quarter to the longer story.

Our track record on this stock

Since the score went from 9 to 12 while the share price moved -13.3% through .

MoonshotScore (0–100, band floors 45 · 65 · 80) Share price, scaled to its own range

The score has stayed in the Weak band across the stretch we have recorded; we grade each band change three months after it happens.

The crowd against our signals

  • Analysts: 100% of 5 rate it a buy; the average target sits +128.3% from the price of $6.57.
  • Last 90 days: 2 rating actions, every one a reaffirmation.
  • Our signals: Weak band; strongest pillar Momentum (82), weakest Business Quality (23).

The crowd is more enthusiastic than our signals. Our Business Quality reading is the main reason.

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $2.02, high $11, latest $6.57. $11 $2.02 high $11 Oct 17, 2025 Nov 19, 2026 · $6.57 $2.40Oct 17, 2025$2.40Oct 31, 2025$2.08Nov 14, 2025$2.36Nov 28, 2025$2.36Dec 12, 2025$2.14Dec 26, 2025$2.33Jan 9, 2026$6.45Jan 23, 2026$6.05Feb 6, 2026$8.70Feb 20, 2026$8.67Mar 6, 2026$8.47Mar 20, 2026$7.30Apr 2, 2026$7.70Apr 17, 2026$7.11May 1, 2026$7.97May 15, 2026$7.52May 29, 2026$7.10Jun 12, 2026$8.71Jun 26, 2026$8.22Jul 10, 2026$7.10Jul 24, 2026$7.64Aug 7, 2026$7.79Aug 21, 2026$8.08Sep 4, 2026$8.48Sep 18, 2026$10Oct 2, 2026$9.18Oct 16, 2026$8.29Oct 30, 2026$6.02Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for ImmunityBio (IBRX): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Weak
Financial Safety Weak
Valuation Neutral
Growth Durability Moderate
Momentum Strong

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Favorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Strong
Gross Margin Strong

Read on: Nov 19, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

Five of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens, Griffin-style lens, Simons-style lens, Englander-style lens and Moon AI lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is ImmunityBio (IBRX), and what does it report?

Short answer · as of

ImmunityBio combines antibody-cytokine fusion proteins, immune-modulating agents, vaccines, natural killer cell therapies, and adaptive T-cell approaches across cancer and infectious-disease programs.

Its economics therefore span commercial product sales and the continuing cost of advancing a broad therapeutic platform.

Reported revenue is almost entirely product revenue, with other product-and-service activity contributing little. The income statement is measuring an emerging commercial business inside a research-heavy biotechnology company, not merely collaboration payments from an otherwise pre-revenue pipeline.

2 · Latest results

What do the latest results show for ImmunityBio (IBRX)?

Revenue has increased throughout the reported quarterly series, and gross profit has remained close to revenue as sales scaled. In the latest period, revenue exceeded the prevailing estimate and the operating loss narrowed, even though research and selling costs together remained well above gross profit.

The commercial progress did not translate into proportionate bottom-line improvement. Net loss and per-share loss were far worse than expected, while operating cash use accelerated sharply; the large separation between operating loss and net loss shows that the headline result was not driven by the core operating deficit alone.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2026$49M-$185M-$0.17 (diluted)
Jun 2026$51M-$230M-$0.22 (diluted)
Mar 2026$44M-$633M-$0.62 (diluted)
Dec 2025$38M-$62M-$0.06 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for ImmunityBio (IBRX)?

Short answer · as of

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

High gross margins and rising product sales are the clearest financial strengths. Cash and short-term investments also support strong near-term liquidity ratios, and the cash balance has improved substantially from its earlier low.

Those strengths sit against debt that materially exceeds cash, persistent operating losses, and a recent acceleration in cash consumption. The estimated runway is limited at the current spending rate, while distress and quality screens remain weak; a stalled product ramp combined with continued research spending would bring financing pressure forward.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -13.30 sits in the distress zone (elevated bankruptcy risk).
  • Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
  • Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at ImmunityBio (IBRX)?

Short answer · as of

Analyst estimates on file carry FY2026 revenue $200.87M · EPS -1.13 · 2 analysts.

Product revenue, operating loss, and operating cash use belong on the same scorecard at the scheduled earnings update. A stronger commercial transition would pair continued sales growth with a narrowing operating deficit and slower cash depletion; another wide gap between operating and net loss would keep attention on financial burdens outside core operations.

Liquidity should be tracked against debt and the current burn rate, not viewed in isolation. Longer-range analyst estimates assume a steep revenue expansion, yet their range is broad and the contributing analyst base thins materially, making actual product-sales progression more informative than the distant averages.

What the records here don't tell us

  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does ImmunityBio compare with its peers?

Short answer

ImmunityBio's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

ImmunityBio differs from pre-revenue biotechnology peers because product sales are already material and carry high reported gross margins. It also differs from mature specialty pharmaceutical businesses because research spending, operating losses, cash burn, and leverage still dominate the financial profile.

That hybrid structure makes commercial execution unusually important: product adoption must fund a platform spanning natural killer cells, adaptive T cells, vaccines, and engineered immune therapies. Pipeline breadth may create additional opportunities, but it also sustains costs while the marketed-product base is still developing.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Kiniksa Pharmaceuticals, Ltd. (KNSA) Same industry, near in market value$95.05 Nov 18, 2026$7.47B98 5-pillar Nov 18, 2026
Krystal Biotech, Inc. (KRYS) Same industry, near in market value$315.34 Nov 18, 2026$9.34B96 5-pillar Nov 18, 2026
Halozyme Therapeutics, Inc. (HALO) Same industry, near in market value$93.04 Nov 19, 2026$10.6B95 5-pillar Nov 18, 2026
Corcept Therapeutics Incorporated (CORT) Same industry, near in market value$67.79 Nov 18, 2026$7.42B91 5-pillar Nov 18, 2026
TG Therapeutics, Inc. (TGTX) Same industry, near in market value$66.12 Nov 18, 2026$9.99B90 5-pillar Nov 18, 2026
Protagonist Therapeutics, Inc. (PTGX) Same industry, near in market value$127.16 Nov 18, 2026$8.30B88 5-pillar Nov 18, 2026
Edgewise Therapeutics, Inc. (EWTX) Same industry, near in market value$41.37 Nov 18, 2026$4.53B84 5-pillar Nov 18, 2026
Caris Life Sciences, Inc. (CAI) Same industry, near in market value$19.50 Nov 18, 2026$5.59B83 5-pillar Nov 18, 2026
Ligand Pharmaceuticals Incorporated (LGND) Same industry, near in market value$298.71 Nov 18, 2026$5.98B71 5-pillar Nov 18, 2026
Oruka Therapeutics, Inc. (ORKA) Same industry, near in market value$95.74 Nov 18, 2026$6.49B67 5-pillar Nov 18, 2026
Erasca, Inc. (ERAS) Same industry, near in market value$13.76 Nov 18, 2026$4.83B67 5-pillar Nov 18, 2026
Veradermics, Incorporated (MANE) Same industry, near in market value$124.86 Nov 18, 2026$5.27B66 5-pillar Nov 18, 2026
ImmunityBio (IBRX) — this page$6.57$6.99B12

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$14.00 – $16.00
Consensus target
$15.00
Median target
$15.00
Revenue estimate
$200.87M
EPS estimate
$-1.13

Consensus record · Captured .

Measured against a quoted price of $6.57 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 5, 2026

Transactions
32
Identified insiders
7
Purchases
0
Sales
8
Other transactions
24

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held IBRX in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported IBRX in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about ImmunityBio (IBRX)?

Read these with our analysis →

ImmunityBio Healthcare Stock: Key Questions Answered

The last 2 questions are answered from this page's own dated data, not from the research.

How do ImmunityBio’s natural killer cell and adaptive T-cell platforms fit its business?

They form part of a wider immunotherapy suite that also includes antibody-cytokine fusion proteins, immune-modulating agents, and vaccine technologies. The platform targets cancers and infectious diseases, so commercial product sales coexist with substantial continuing research activity.

Why does rising product revenue not yet make ImmunityBio self-funding?

Gross profit has grown with product sales, but research and selling costs remain larger than gross profit and operations continue to consume cash. Commercial growth therefore has not yet absorbed the cost of the wider platform.

What makes ImmunityBio’s latest net loss different from its operating loss?

The operating deficit narrowed while the net loss remained far larger, creating an unusually wide separation between core operating performance and the bottom line. The per-share result also missed expectations despite revenue exceeding the estimate.

Can ImmunityBio fund its immunotherapy rollout from current cash?

Current cash and short-term investments support near-term liquidity, but they remain below total debt and imply limited runway at the prevailing burn rate. Continued product growth, slower cash use, or additional financing would be needed to extend that position.

What is the IBRX stock price today?

The last price recorded for ImmunityBio, Inc. (IBRX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the IBRX price target?

The analyst consensus price target for ImmunityBio, Inc. (IBRX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 25 figures on this page — 1 from SEC filings and earnings calls, 16 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Legal name; Ticker / exchange; Business description; Revenue by segment; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash, investments and debt
  • 1. What is ImmunityBio (IBRX), and what does it report?: Business description; Sector / industry (provider taxonomy); Revenue by segment; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands)
  • 2. What do the latest results show for ImmunityBio (IBRX)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Trailing twelve-month ratio set; Operating cash flow by quarter (USD millions); Reported versus estimated, last 8 quarters; Most recent periodic reports
  • 3. What are the financial strengths and risks for ImmunityBio (IBRX)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash runway cross-check (ours); Cash against market value; Trailing twelve-month ratio set; Distress and quality screens
  • 4. What should you watch next at ImmunityBio (IBRX)?: Next earnings report; Analyst revenue and earnings estimates (average); Reported versus estimated, last 8 quarters; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash runway cross-check (ours); Cash against market value; Recent SEC filings
  • 5. How does ImmunityBio compare with its peers?: Sector / industry (provider taxonomy); Business description; Revenue by segment; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash, investments and debt; Trailing twelve-month ratio set
  • FAQ: How do ImmunityBio’s natural killer cell and adaptive T-cell platforms fit its business?: Business description; Revenue by segment; Annual revenue and net result (USD millions)
  • FAQ: Why does rising product revenue not yet make ImmunityBio self-funding?: Quarterly income statement (USD thousands); Revenue by segment; Operating cash flow by quarter (USD millions); Trailing twelve-month ratio set
  • FAQ: What makes ImmunityBio’s latest net loss different from its operating loss?: Quarterly income statement (USD thousands); Reported versus estimated, last 8 quarters
  • FAQ: Can ImmunityBio fund its immunotherapy rollout from current cash?: Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Operating cash flow by quarter (USD millions); Cash runway cross-check (ours); Cash against market value
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.